A detailed history of Sherbrooke Park Advisers LLC transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 23,326 shares of XERS stock, worth $87,472. This represents 0.03% of its overall portfolio holdings.

Number of Shares
23,326
Holding current value
$87,472
% of portfolio
0.03%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$2.78 - $3.73 $64,846 - $87,005
23,326 New
23,326 $79.1 Million

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $510M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Sherbrooke Park Advisers LLC Portfolio

Follow Sherbrooke Park Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sherbrooke Park Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sherbrooke Park Advisers LLC with notifications on news.